Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.
Acesion Pharma: New head of finance
AppointmentsPharmaMar: Pushing the borders
AppointmentsBIA: Three new faces on the board
AppointmentsMedigene offers neoantigen-specific TCRs
Latest NewsUntil mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.